ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation Of The Phase 3 HARMONY Study Of Pimavanserin In Dementia-Related Psychosis At The Clinical Trials on Alzheimer's Disease (CTAD) 2019 Meeting Dec 4th